Cargando…
Irisin reduces bone fracture by facilitating osteogenesis and antagonizing TGF-β/Smad signaling in a growing mouse model of osteogenesis imperfecta()()
OBJECTIVE: Osteogenesis imperfecta (OI) is a congenital disorder characterized by muscle defect and skeletal fragility, and no cure is yet available. Crosstalk between bone and muscle has become a new coming focus of therapeutic strategy in OI. Irisin, a secreted myokine, was found to be involved in...
Autores principales: | Sun, Bin, Wu, Huiqiao, Lu, Jiajia, Zhang, Rongcheng, Shen, Xiaolong, Gu, Yifei, Shi, Changgui, Zhang, Ying, Yuan, Wen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chinese Speaking Orthopaedic Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672882/ https://www.ncbi.nlm.nih.gov/pubmed/36439629 http://dx.doi.org/10.1016/j.jot.2022.10.012 |
Ejemplares similares
-
Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta
por: Shi, Changgui, et al.
Publicado: (2021) -
Targeting TGF-β for treatment of osteogenesis imperfecta
por: Song, I-Wen, et al.
Publicado: (2022) -
Osteogenesis imperfecta
por: Vitturi, Bruno Kusznir, et al.
Publicado: (2018) -
Osteogenesis Imperfecta
por: Sam, Justin Easow, et al.
Publicado: (2017) -
Management of Osteogenesis Imperfecta
por: Ralston, Stuart H., et al.
Publicado: (2020)